Evidence map›Paper›PMID 35832345›Full record

ArticleHeliyon2022

Celecoxib-mediated attenuation of non-alcoholic steatohepatitis is potentially relevant to redistributing the expression of adiponectin receptors in rats.

Guoying Zhu, Li Chen, Su Liu, Ling She, Yongnian Ding, Changqing Yang, Fengshang Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Guoying ZhuDepartment of Clinical Nutrition, Putuo People's Hospital, School of Medicine, Tongji University, Shanghai, 200060, China.
Li ChenDepartment of Gastroenterology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
Su LiuDepartment of Gastroenterology, Zhabei Central Hospital of Jingan District, Shanghai, 200070, China.
Ling SheState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia & Xinjiang Key Laboratory of Neurological Disorder Research, Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, 830000, China.
Yongnian DingState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia & Xinjiang Key Laboratory of Neurological Disorder Research, Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, 830000, China.
Changqing YangDepartment of Gastroenterology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
Fengshang ZhuState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia & Xinjiang Key Laboratory of Neurological Disorder Research, Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, 830000, China.
Tongji University · CNXinjiang Medical University · CNShanghai Zhabei District Shibei Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacological inhibition of cyclooxygenase-2 (COX-2) activity ameliorated the severity of non-alcoholic steatohepatitis (NASH) rats. It is not completely understood that the role of COX-2 inhibitor celecoxib on adiponectin receptors (Adipo-R1/R2) expression in different tissues in NASH rats. Sprague-Dawley male NASH rats induced by a high-fat diet (HFD) were administrated with or without celecoxib for 8 weeks. Biochemical parameters of liver function, glucose, and lipid metabolism, and the levels of adiponectin, tumor necrosis factor-alpha (TNF-α), prostaglandin E

Indexed as

AdiponectinAdiponectin receptorCelecoxibNon-alcoholic steatohepatitis

Identifiers

PMID35832345
PMCPMC9272346
OpenAlexW4283817082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.